Format

Send to

Choose Destination
Ann Surg. 2014 Jul;260(1):31-6. doi: 10.1097/SLA.0000000000000559.

A randomized, controlled, crossover study of sacral nerve stimulation for irritable bowel syndrome.

Author information

1
*Department of Surgery P †Neurogastroenterology Unit, Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus C, Denmark.

Abstract

OBJECTIVE:

To investigate whether sacral nerve stimulation reduces irritable bowel syndrome (IBS)-specific symptoms by a randomized, controlled, crossover study.

BACKGROUND:

IBS affects 3% to 22% of the population worldwide, but most patients continue to have symptoms despite treatment.

METHODS:

Patients included from our tertiary center had diarrhea-predominant or mixed IBS, with a minimum baseline IBS symptom score (Gastrointestinal Syndrome Rating Scale-IBS questionnaire) of 40 points reduced by a minimum of 30% during the percutaneous nerve evaluation before permanent implantation. Patients were randomized (1:1) to have the stimulator ON or OFF for 1 month and then the opposite for another month. Investigators and patients were not informed of the setting. IBS-specific symptoms and quality of life were assessed through bowel diaries and validated questionnaires. Primary endpoint was the IBS-specific symptom score.

RESULTS:

Twenty-one patients were randomized. Ten were eligible for analysis in each group. IBS-specific symptom scores were significantly reduced during stimulation: the median difference in the ON-OFF group was 12 (range, -22 to 44) and in the OFF-ON group -17.5 (range, -48 to -1) (P = 0.0009). IBS-specific quality-of-life scores improved significantly during stimulation: the median difference in the ON-OFF group was 16 (range, -24 to 69) and in the OFF-ON group -42.5 (range, -77 to 0) (P = 0.0003). At 1-year follow-up, the median IBS-specific symptom score (25; range, 13-65) was significantly lower than that at baseline (62; range, 45-80) (P = 0.0001).

CONCLUSIONS:

Sacral nerve stimulation significantly reduces symptoms and improves quality of life of highly selected patients with IBS.

PMID:
24509204
DOI:
10.1097/SLA.0000000000000559
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center